Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Preclinical Cro Market by Services (Bioanalysis and DMPK Studies, Toxicology Testing, Safety Pharmacology, Others), by Animal Model (Small Animal Model, Large Animal Model) and by End User (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies): Global Opportunity Analysis and Industry Forecast, 2023-2032

A08286

Pages: NA

Charts: NA

Tables: NA

A preclinical CRO or preclinical contract research organization provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental & industry liaisons, marketing experts, and a host of other technical and creative individuals. The CRO industry emerged to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible. The continental divide in CROs is preclinical and clinical. The former consists of subdivisions largely grouped into drug screening/design control, compound synthesis/device manufacturing, toxicology/biocompatibility, and efficacy/functional repair. The latter has operations in a flow of phases in human trials to meet regulatory requirements. Moreover, the medical industry executives have realized that a faster turnaround to their investment in R&D may come from joint ventures with similar-minded competitors. It is well known that unbiased data should be generated by an independent third party to convince corporate partners and regulatory bodies. 

COVID-19 scenario analysis:

  • Pharmaceutical and biotech companies together with governments across the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. 
  • Moreover, commonly used drugs, such as hydroxychloroquine, have witnessed dramatic surge in demand for the treatment of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 drugs as many developed countries are short of these drugs. 
  • The pharmaceutical and biotechnology industry is expected to witness significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. To conduct clinical trials of COVID-19, the sample product needs to be transported from one country to another; however, due to the pandemic, import-export between countries is prohibited. Therefore, majority of healthcare, pharmaceutical, and biotechnology organizations have concentrated on diagnostics kits, safety wearables (PPE kits, face shields, masks), treatment therapies, and medication to fight against the novel coronavirus. This is expected to increase the use of preclinical CRO. 

Top impacting factors: Market scenario analysis, trends, drivers, and impact analysis

The market is expected to experience growth due to increase in R&D expenditure and rise in outsourcing trend, which are expected to increase the demand for preclinical trials in the future. Increase in competition between top players leads to rise in use of preclinical CRO market. As companies try to introduce new and advanced products, they need do complete their study regarding competitors. In addition, clinical trial is an important phase before introducing any product and to get better results, companies depend on contract research organizations. In addition, with increase in new and complex microorganism causing different diseases, complex drugs are entering clinical trials and increasing R&D expenses. These are some of the factors responsible for the preclinical Contract Research Organization (CRO) growth. Therefore, increase in technology and advancements in healthcare infrastructure are expected to foster the preclinical CRO market growth. 

Top CROs and their services

Envigo Corporation provides the broadest range of research models and related services to the pharmaceutical and biotechnology industries, government, academia, and other life science organizations. Envigo Corporation uses different research models, such as browse research models, search research models, models by therapeutic area, oncology model sampling program, and pricing, to provide consulting to companies. Research services provided by Envigo include genetically engineered models & services, full spectrum health monitoring, custom antibody production services, biological products & services, contract breeding services, genetic testing services, pharmaceutical development, surgical services, research model support services, and others. IQVIA is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials, associated laboratory, and analytical services, including consulting services. Furthermore, IQVIA uses a new technology IQVIA CORE to provide best services to its customers.

Key benefits of the report:

  • This study presents the analytical depiction of the preclinical CRO market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the preclinical CRO market share.
  • The current market is quantitatively analyzed to highlight the preclinical CRO market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the preclinical CRO market research report:

  • Which are the leading market players active in the market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the preclinical CRO market?
  • What are the projections for the future that would help in taking further strategic steps?

 Key Market Segments

  • By Services
    • Bioanalysis and DMPK Studies
    • Toxicology Testing
    • Safety Pharmacology
    • Others
  • By Animal Model
    • Small Animal Model
    • Large Animal Model
      • Nonhuman Primates NHP
      • Others
  • By End User
    • Biopharmaceutical Companies
    • Government and Academic Institutes
    • Medical Device Companies
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA

 
Key Market Players

  • Laboratory Corporation Of America Holdings
  • BIOEMTECH
  • Simavita Ltd
  • Global Center For Medical Innovation
  • CYNBIOSE
  • Eurofins Scientific
  • Vivotecnia
  • Charles River Laboratories International, Inc.
  • AmplifyBio
  • Altasciences

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: PRECLINICAL CRO MARKET, BY SERVICES

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Services

    • 4.2. Bioanalysis And DMPK Studies

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Toxicology Testing

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Safety Pharmacology

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: PRECLINICAL CRO MARKET, BY ANIMAL MODEL

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Animal Model

    • 5.2. Small Animal Model

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Large Animal Model

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

      • 5.3.4. Nonhuman Primates NHP

        • 5.3.4.1. Market Size and Forecast

      • 5.3.4. Others

        • 5.3.4.1. Market Size and Forecast

  • CHAPTER 6: PRECLINICAL CRO MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Biopharmaceutical Companies

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Government And Academic Institutes

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Medical Device Companies

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: PRECLINICAL CRO MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Services

      • 7.2.3. Market Size and Forecast, By Animal Model

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Preclinical Cro Market

        • 7.2.6.1. Market Size and Forecast, By Services
        • 7.2.6.2. Market Size and Forecast, By Animal Model
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Preclinical Cro Market

        • 7.2.7.1. Market Size and Forecast, By Services
        • 7.2.7.2. Market Size and Forecast, By Animal Model
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Preclinical Cro Market

        • 7.2.8.1. Market Size and Forecast, By Services
        • 7.2.8.2. Market Size and Forecast, By Animal Model
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Services

      • 7.3.3. Market Size and Forecast, By Animal Model

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Preclinical Cro Market

        • 7.3.6.1. Market Size and Forecast, By Services
        • 7.3.6.2. Market Size and Forecast, By Animal Model
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Preclinical Cro Market

        • 7.3.7.1. Market Size and Forecast, By Services
        • 7.3.7.2. Market Size and Forecast, By Animal Model
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Preclinical Cro Market

        • 7.3.8.1. Market Size and Forecast, By Services
        • 7.3.8.2. Market Size and Forecast, By Animal Model
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Preclinical Cro Market

        • 7.3.9.1. Market Size and Forecast, By Services
        • 7.3.9.2. Market Size and Forecast, By Animal Model
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Preclinical Cro Market

        • 7.3.10.1. Market Size and Forecast, By Services
        • 7.3.10.2. Market Size and Forecast, By Animal Model
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Preclinical Cro Market

        • 7.3.11.1. Market Size and Forecast, By Services
        • 7.3.11.2. Market Size and Forecast, By Animal Model
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Preclinical Cro Market

        • 7.3.12.1. Market Size and Forecast, By Services
        • 7.3.12.2. Market Size and Forecast, By Animal Model
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Services

      • 7.4.3. Market Size and Forecast, By Animal Model

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Preclinical Cro Market

        • 7.4.6.1. Market Size and Forecast, By Services
        • 7.4.6.2. Market Size and Forecast, By Animal Model
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Preclinical Cro Market

        • 7.4.7.1. Market Size and Forecast, By Services
        • 7.4.7.2. Market Size and Forecast, By Animal Model
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Preclinical Cro Market

        • 7.4.8.1. Market Size and Forecast, By Services
        • 7.4.8.2. Market Size and Forecast, By Animal Model
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Preclinical Cro Market

        • 7.4.9.1. Market Size and Forecast, By Services
        • 7.4.9.2. Market Size and Forecast, By Animal Model
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Preclinical Cro Market

        • 7.4.10.1. Market Size and Forecast, By Services
        • 7.4.10.2. Market Size and Forecast, By Animal Model
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Preclinical Cro Market

        • 7.4.11.1. Market Size and Forecast, By Services
        • 7.4.11.2. Market Size and Forecast, By Animal Model
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Preclinical Cro Market

        • 7.4.12.1. Market Size and Forecast, By Services
        • 7.4.12.2. Market Size and Forecast, By Animal Model
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Preclinical Cro Market

        • 7.4.13.1. Market Size and Forecast, By Services
        • 7.4.13.2. Market Size and Forecast, By Animal Model
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Preclinical Cro Market

        • 7.4.14.1. Market Size and Forecast, By Services
        • 7.4.14.2. Market Size and Forecast, By Animal Model
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Services

      • 7.5.3. Market Size and Forecast, By Animal Model

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Preclinical Cro Market

        • 7.5.6.1. Market Size and Forecast, By Services
        • 7.5.6.2. Market Size and Forecast, By Animal Model
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Preclinical Cro Market

        • 7.5.7.1. Market Size and Forecast, By Services
        • 7.5.7.2. Market Size and Forecast, By Animal Model
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Preclinical Cro Market

        • 7.5.8.1. Market Size and Forecast, By Services
        • 7.5.8.2. Market Size and Forecast, By Animal Model
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Preclinical Cro Market

        • 7.5.9.1. Market Size and Forecast, By Services
        • 7.5.9.2. Market Size and Forecast, By Animal Model
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Preclinical Cro Market

        • 7.5.10.1. Market Size and Forecast, By Services
        • 7.5.10.2. Market Size and Forecast, By Animal Model
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Preclinical Cro Market

        • 7.5.11.1. Market Size and Forecast, By Services
        • 7.5.11.2. Market Size and Forecast, By Animal Model
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Eurofins Scientific

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Laboratory Corporation Of America Holdings

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. CYNBIOSE

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Charles River Laboratories International, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. AmplifyBio

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Vivotecnia

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Simavita Ltd

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. BIOEMTECH

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Altasciences

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Global Center For Medical Innovation

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PRECLINICAL CRO MARKET, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL PRECLINICAL CRO MARKET FOR BIOANALYSIS AND DMPK STUDIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL PRECLINICAL CRO MARKET FOR TOXICOLOGY TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL PRECLINICAL CRO MARKET FOR SAFETY PHARMACOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL PRECLINICAL CRO MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL PRECLINICAL CRO MARKET, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL PRECLINICAL CRO MARKET FOR SMALL ANIMAL MODEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL PRECLINICAL CRO MARKET FOR LARGE ANIMAL MODEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL PRECLINICAL CRO MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL PRECLINICAL CRO MARKET FOR GOVERNMENT AND ACADEMIC INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL PRECLINICAL CRO MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA PRECLINICAL CRO, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. U.S. PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 19. U.S. PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 20. U.S. PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. CANADA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 22. CANADA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 23. CANADA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. MEXICO PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE PRECLINICAL CRO, BY REGION, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. FRANCE PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. GERMANY PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. ITALY PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 38. ITALY PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 39. ITALY PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. SPAIN PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. UK PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 44. UK PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 45. UK PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. RUSSIA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. REST OF EUROPE PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. ASIA-PACIFIC PRECLINICAL CRO, BY REGION, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. CHINA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 57. CHINA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 58. CHINA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. JAPAN PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. INDIA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 63. INDIA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 64. INDIA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH KOREA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. AUSTRALIA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. THAILAND PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. MALAYSIA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. INDONESIA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. LAMEA PRECLINICAL CRO, BY REGION, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 87. BRAZIL PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH AFRICA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. UAE PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 97. UAE PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 98. UAE PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. ARGENTINA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. REST OF LAMEA PRECLINICAL CRO, BY SERVICES, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA PRECLINICAL CRO, BY ANIMAL MODEL, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA PRECLINICAL CRO, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. EUROFINS SCIENTIFIC: KEY EXECUTIVES
  • TABLE 106. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 107. EUROFINS SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 108. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 109. EUROFINS SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY EXECUTIVES
  • TABLE 111. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
  • TABLE 112. LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
  • TABLE 113. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 114. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. CYNBIOSE: KEY EXECUTIVES
  • TABLE 116. CYNBIOSE: COMPANY SNAPSHOT
  • TABLE 117. CYNBIOSE: OPERATING SEGMENTS
  • TABLE 118. CYNBIOSE: PRODUCT PORTFOLIO
  • TABLE 119. CYNBIOSE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY EXECUTIVES
  • TABLE 121. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
  • TABLE 122. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS
  • TABLE 123. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
  • TABLE 124. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. AMPLIFYBIO: KEY EXECUTIVES
  • TABLE 126. AMPLIFYBIO: COMPANY SNAPSHOT
  • TABLE 127. AMPLIFYBIO: OPERATING SEGMENTS
  • TABLE 128. AMPLIFYBIO: PRODUCT PORTFOLIO
  • TABLE 129. AMPLIFYBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. VIVOTECNIA: KEY EXECUTIVES
  • TABLE 131. VIVOTECNIA: COMPANY SNAPSHOT
  • TABLE 132. VIVOTECNIA: OPERATING SEGMENTS
  • TABLE 133. VIVOTECNIA: PRODUCT PORTFOLIO
  • TABLE 134. VIVOTECNIA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. SIMAVITA LTD: KEY EXECUTIVES
  • TABLE 136. SIMAVITA LTD: COMPANY SNAPSHOT
  • TABLE 137. SIMAVITA LTD: OPERATING SEGMENTS
  • TABLE 138. SIMAVITA LTD: PRODUCT PORTFOLIO
  • TABLE 139. SIMAVITA LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. BIOEMTECH: KEY EXECUTIVES
  • TABLE 141. BIOEMTECH: COMPANY SNAPSHOT
  • TABLE 142. BIOEMTECH: OPERATING SEGMENTS
  • TABLE 143. BIOEMTECH: PRODUCT PORTFOLIO
  • TABLE 144. BIOEMTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. ALTASCIENCES: KEY EXECUTIVES
  • TABLE 146. ALTASCIENCES: COMPANY SNAPSHOT
  • TABLE 147. ALTASCIENCES: OPERATING SEGMENTS
  • TABLE 148. ALTASCIENCES: PRODUCT PORTFOLIO
  • TABLE 149. ALTASCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. GLOBAL CENTER FOR MEDICAL INNOVATION: KEY EXECUTIVES
  • TABLE 151. GLOBAL CENTER FOR MEDICAL INNOVATION: COMPANY SNAPSHOT
  • TABLE 152. GLOBAL CENTER FOR MEDICAL INNOVATION: OPERATING SEGMENTS
  • TABLE 153. GLOBAL CENTER FOR MEDICAL INNOVATION: PRODUCT PORTFOLIO
  • TABLE 154. GLOBAL CENTER FOR MEDICAL INNOVATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PRECLINICAL CRO MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PRECLINICAL CRO MARKET
  • FIGURE 3. SEGMENTATION PRECLINICAL CRO MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PRECLINICAL CRO MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPRECLINICAL CRO MARKET
  • FIGURE 11. PRECLINICAL CRO MARKET SEGMENTATION, BY BY SERVICES
  • FIGURE 12. PRECLINICAL CRO MARKET FOR BIOANALYSIS AND DMPK STUDIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. PRECLINICAL CRO MARKET FOR TOXICOLOGY TESTING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. PRECLINICAL CRO MARKET FOR SAFETY PHARMACOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. PRECLINICAL CRO MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. PRECLINICAL CRO MARKET SEGMENTATION, BY BY ANIMAL MODEL
  • FIGURE 17. PRECLINICAL CRO MARKET FOR SMALL ANIMAL MODEL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. PRECLINICAL CRO MARKET FOR LARGE ANIMAL MODEL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. PRECLINICAL CRO MARKET SEGMENTATION, BY BY END USER
  • FIGURE 20. PRECLINICAL CRO MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. PRECLINICAL CRO MARKET FOR GOVERNMENT AND ACADEMIC INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. PRECLINICAL CRO MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: PRECLINICAL CRO MARKET
  • FIGURE 29. TOP PLAYER POSITIONING, 2024
  • FIGURE 30. EUROFINS SCIENTIFIC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. EUROFINS SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. EUROFINS SCIENTIFIC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. LABORATORY CORPORATION OF AMERICA HOLDINGS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. LABORATORY CORPORATION OF AMERICA HOLDINGS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. CYNBIOSE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. CYNBIOSE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. CYNBIOSE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. AMPLIFYBIO: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. AMPLIFYBIO: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. AMPLIFYBIO: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. VIVOTECNIA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. VIVOTECNIA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. VIVOTECNIA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. SIMAVITA LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. SIMAVITA LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. SIMAVITA LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. BIOEMTECH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. BIOEMTECH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. BIOEMTECH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. ALTASCIENCES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. ALTASCIENCES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. ALTASCIENCES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. GLOBAL CENTER FOR MEDICAL INNOVATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. GLOBAL CENTER FOR MEDICAL INNOVATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. GLOBAL CENTER FOR MEDICAL INNOVATION: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Preclinical Cro Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved